![PDF) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01 PDF) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01](https://i1.rgstatic.net/publication/338200405_A_phase_2_study_of_trametinib_for_patients_with_pediatric_glioma_or_plexiform_neurofibroma_with_refractory_tumor_and_activation_of_the_MAPKERK_pathway_TRAM-01/links/5e06b0b0299bf10bc37e2a9c/largepreview.png)
PDF) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
![PDF) Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report PDF) Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report](https://i1.rgstatic.net/publication/358630882_Myositis_with_prominent_B-cell_aggregates_causing_shrinking_lung_syndrome_in_systemic_lupus_erythematosus_a_case_report/links/620d99f06c472329dced9bb9/largepreview.png)
PDF) Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report
![Jean MATHIEU | Professor (Associate) | MD, MSc, Associate professor | Université de Sherbrooke, Sherbrooke | UdeS | School of Rehabilitation | Research profile Jean MATHIEU | Professor (Associate) | MD, MSc, Associate professor | Université de Sherbrooke, Sherbrooke | UdeS | School of Rehabilitation | Research profile](https://i1.rgstatic.net/ii/profile.image/272357868699658-1441946584679_Q512/Jean-Mathieu.jpg)